Summary
The antiparkinsonian activity of several dopamine agonists was investigated in an animal model and clinically in parkinsonian patients. The semisynthetic ergoline, pergolide, the partial ergoline, LY 141865 and the 8-α-aminoergoline, CU 32-085 were found to be effective antitremor agents in monkeys with ventromedial tegmental lesions. The administration of pergolide or LY 141865 results in a relief of tremor with a concomitant occurrence of severe abnormal involuntary movements, while the administration of CU 32-085 results in a relief of tremor with the occurrence of only minor abnormal involuntary movements. Clinical studies have revealed that pergolide is an effective drug in patients with advanced Parkinson’s disease, and it reduces the “on-off” phenomena. The possible regulation of dopamine neurotransmission by the norepinephrine neuronal systems was reviewed. Preliminary data suggest that clonidine may interact with presynaptic dopamine receptors.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Antelman, S. M., Caggiula, A. R.: Norepinephrine-dopamine interactions and behavior. Science 195, 646–653 (1977).
Di Paolo, T., Poyet, P., Labrie, F.: Effect of chronic estradiol and haloperidol treatment on striatal dopamine receptors. Eur. J. Pharmacology 73, 105–106 (1981).
Engel, J. A., Johannessen, K., Liljequist, S., Goldstein, M.: Enhancement of the haloperidol-induced suppression of food-reinforced lever-pressing behavior by interaction with a2-adrenoreceptors. Abstract, Society for Neuroscience, Minneapolis, Minn., 1982.
Enz, A.: Biphasic influence of a Sa-amino ergoline, CU 32–085, on striatal dopamine synthesis and turnover in vivo in the rat. Life Sci. 29, 2227–2234 (1981).
Fields, J.Z., Gordon, J. H.: Estrogen inhibits the dopaminergic supersensitiv- ity induced by neuroleptics. Life Sciences 30, 229–234 (1982).
Freedman, R., Kirch, D., Bell, J Adler, L. E., Pecevich, M., Pachtman, E., Denver, P.: Clonidine treatment of schizophrenia: Double-blind comparison to placebo and neuroleptic drugs. Acta psychiat. scand. 65, 35–45 (1982).
Fuxe, K., Fredholm, B. B., Ogren, S.-O., Agnati, L. F., Hökfelt, T, Gustafsson, J. A.: Ergot drugs and central monoaminergic mechanisms: A histochemical, biochemical and behavioral analysis. Fed. Proc. 37, 2181–2191 (1978).
Glaeser, B. S., Berry, J. C., Boyar, W. C., Lovell, R.A.: Effect of acute clonidine administration on striatal dopamine autoreceptors. Abstract, Society for Neuroscience, Minneapolis, Minn., 1982.
Goldstein, M., Battista, A. F., Ohmoto, T., Anagnoste, B., Fuxe, K.: Tremor and involuntary movements in monkeys: Effects of L-dopa and of a dopamine receptor stimulating agent. Science 179, 816 (1973).
Goldstein, M., Lew, J. Y., Nakamura, S., Battista, A., Lieberman, A., Fuxe, K.: Dopaminophilic properties of ergot alkaloids. Fed. Proc. 37, 2202–2206 (1978).
Goldstein, M., Lew,J. Y., Sauter, A., Lieberman, A.: The affinities of ergot compounds for dopamine and dopamine antagonist receptor sites. In: Ergot Compounds and Brain Function: Neuroendocrine and Neuropsychiatric Aspects, pp. 75–82. New York: Raven Press. 1980.
Goldstein, M., Lieberman, A., Lew, J. Y., Asano, T, Rosenfeld, M., Makman, M. H.: Interaction of pergolide with central dopaminergic receptors. Proc. nat. Acad. Sci. (U.S.A.) 6, 3725–3728 (1980).
Jellinger, K.: Adjuvant treatment of Parkinson’s disease with dopamine agonists: Open trial with bromocriptine and CU 32–085. J. Neurol. 227, 75–88 (1982).
Kostowski, W., Jerlicz, M., Bidzinski, A., Hauptmann, M.: Evidence for existence of two opposite noradrenergic brain systems controlling behavior. Psychopharmacology 59, 311–312 (1978).
Poirier, L.J., Sourkes, T. L.: Influence of the substantia nigra on the catecholamine content of the striatum. Brain 88, 181–189 (1965).
Rabey, J. M., Passeltiner, P., Markey, K., Asano, T, Goldstein, M.: Stimulation of pre- and postsynaptic dopamine receptors by an ergoline and by a partial ergoline. Brain Res. 225, 347–356 (1981).
Rabey, J M., Passeltiner, P., Bystritsky, A., Engel, J., Goldstein, M.: The regulation of striatal DOPA synthesis by r2-adrenoreceptors. Brain Research 230, 422–426 (1981 a).
Ringwald, E., Hirt, D., Markstein, R., Vigouret, J. M.: Dopamine Rezeptoren-Stimulation in der Behandlung der Parkinson-Krankheit. Nervenarzt 53, 67–71 (1982).
Sailer, C.F., Chiodo, L.A.: Glucose suppresses basal firing and haloperidol-induced increases in the firing rate of central dopaminergic neurons. Science 210, 1269–1271 (1980).
Sailer, C.F., Kopin, I.J.: Glucose potentiates haloperidol-induced catalepsy. Life Sci. 29, 2337–2341 (1981).
Ungerstedt, U.: Stereotaxic mapping of the monoamine pathways in the rat brain. Acta physiol. Scand. Suppl. 367, 1–48 (1971).
Walters,J. R., Roth, R. H.: Dopaminergic neurons: An in-vivo system for measuring drug interactions with presynaptic receptors. Naunyn-Schmiedeberg’s Arch. Pharmacol. 26, 5–12 (1976).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1983 Springer-Verlag Wien
About this paper
Cite this paper
Goldstein, M., Engel, J., Lieberman, A., Regev, I., Bystritsky, A., Mino, S. (1983). Therapeutic Potentials of Centrally Acting Dopamine and α 2-Adrenoreceptor Agonists. In: Goldstein, M., Jellinger, K., Riederer, P. (eds) Basic Aspects of Receptor Biochemistry. Journal of Neural Transmission, vol 18. Springer, Vienna. https://doi.org/10.1007/978-3-7091-4408-4_24
Download citation
DOI: https://doi.org/10.1007/978-3-7091-4408-4_24
Publisher Name: Springer, Vienna
Print ISBN: 978-3-7091-4410-7
Online ISBN: 978-3-7091-4408-4
eBook Packages: Springer Book Archive